Author details
Author Valérie Paris |
Available item(s) by this author (1)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Pharmaceutical pricing policies in a global market / Elizabeth Docteur ; Valérie Paris ; Pierre Moise ; Organisation for Economic Co-operation and Development (OECD) = Organisation de Coopération et de Développement Economiques (OCDE) / Paris : OECD (2008)
Pharmaceutical pricing policies in a global market ; Les prix des médicaments sur un marché global [printed text] / Elizabeth Docteur ; Valérie Paris ; Pierre Moise ; Organisation for Economic Co-operation and Development (OECD) = Organisation de Coopération et de Développement Economiques (OCDE) . - Paris : OECD, 2008 . - 215 p. : col. ill. ; 27 cm. - (OECD Health Policy Studies) .
ISBN : 978-92-64-04414-2 : € 50,00
Languages : English (eng)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
Economics, Pharmaceutical ; Government Publications [PT] ; Pharmaceutical Preparations ; Prices ; Public PolicyClass number: 338.436151 Abstract: Pharmaceutical pricing policies are designed with national objectives in mind, but are the transnational implications always taken into account?
This report assesses how pharmaceutical pricing and reimbursement policies have contributed to the achievement of certain health policy objectives. It examines the national and transnational effects of these policies, in particular, their implications for the availability of medicines in other countries, the prices of these medicines, and innovation in the pharmaceutical sector.
This publication presents an analysis of comparative price levels, making use of a unique dataset to construct the most comprehensive pan-OECD pharmaceutical price index to date. It also draws upon original case studies of pharmaceutical pricing and reimbursement policies in six OECD countries to provide specific examples of the impacts of policies on health system performance.Contents note: Executive Summary – Introduction -- Chapter 1. Key Characteristics of the Pharmaceutical Sector in OECD Economies -- Pharmaceutical expenditures -- Pharmaceutical consumption and relative price levels determine pharmaceutical expenditures -- Financing -- The pharmaceutical industry is important in the economies of several OECD countries -- Annex 1.A1. Distribution Mark-ups and Value-added tax for Pharmaceuticals in OECD Countries -- Chapter 2. The Pharmaceutical Industry and its Activities -- Concentration of the industry -- Research and development -- Pharmaceutical manufacturing -- Pharmaceutical sales -- Ex-manufacturer prices -- Product life-cycle management -- Profits of the pharmaceutical industry -- Annex 2.A1. Price Comparisons at the Ex-manufacturer Level -- Chapter 3. Pharmaceutical Pricing and Reimbursement and the Broader Pharmaceutical Policy -- Environment -- Coverage schemes -- Pharmaceutical price regulation -- Regulators, payers and purchasers use a mix of techniques for defining price levels -- All components of the retail price of pharmaceuticals are subject to regulation -- Many OECD countries regulate price increases and try to contain pharmaceutical expenditure growth -- The stability, consistency and predictability of regulation -- Other aspects of the pharmaceutical policy environment that affect the achievement of policy goals -- Annex 3.A1. Pharmaceuticals and Intellectual Property Rights in the European Union -- Annex 3.A2. Marketing Authorisation in the European Economic Area -- Chapter 4. The Impact of Pharmaceutical Pricing Policies on Performance in Meeting Health Policy Goals -- Promoting public health -- The impact of pricing and reimbursement policies on pharmaceutical price levels -- Pharmaceutical cost containment -- Pursuing good value for money in spending on pharmaceuticals -- Annex 4.A1. The Relationship between Retail Pharmaceutical Price Levels and Economy-wide Price Levels in OECD Countries -- Chapter 5. The Impact of National Pricing and Reimbursement Practices on Prices and Availability of Medicines in Other Countries -- National pricing policies are likely to impact the availability and prices of drugs in foreign countries -- Manufacturers use various strategies in order to maximise net revenues in the global market and counter spill-over effects of national policies -- There is some evidence of market entry price convergence among OECD countries -- Chapter 6. The Impact of Pharmaceutical Pricing Policies on Pharmaceutical Innovation -- Pharmaceutical R&D investment -- Ways in which pricing and reimbursement practices contribute to trends in innovation
Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1471 Hold
Place a hold on this item
Copies(1)
Barcode Call number Media type Location Section Status 10273-01609 QV 736/DOC Book KCE Library (10.124) Available E-copies
Executive summaryURLReaders who borrowed this document also borrowed:
Clinical trials Brody, Tom Statistical analysis with missing data Little, Roderick J.A. A good life in old age? Organisation for Economic Co-operation and Development, European Commission Survival Analysis Using SAS Allison, Paul David Cancer Care PROC SQL by Example Schreier, Howard Analysing survival data from clinical trials and observational studies Marubini, Ettore The socio-economic burden of hospital acquired infection Plowman, Rosalind Le financement des hôpitaux en Belgique Durant, G. Design and analysis of clinical trials Chow, Shein-Chung Methods for the Economic Evaluation of Health Care Programmes Drummond, Michael F.